Q1 2016

Source filing unavailable

Q1 2016 · —

Revenue

$13.05M

+150.6% vs Q1 2015

Net Income

-$35.44M

N/M vs Q1 2015

EPS Diluted

-$0.42

N/M vs Q1 2015

Gross Profit$5,071,000+286.8%

Operating Income-$31,938,000N/M

Operating Cash Flow-$30,977,000

Same quarter

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR